Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 17/20 | 0.42 |
| ▸ | MTOR | P42345 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.38 |
| ▸ | DLK1 | P80370 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367412 | 0.76 | KCNQ3 (0.43) | MAP3K12MTORPIK3CA | |
| SCHEMBL2143738 | 0.76 | KCNQ3 (0.43) | MAP3K12MTORPIK3CA | |
| SCHEMBL30749108 | 0.76 | MAP3K12 (0.48) | MAP3K12MTORPIK3CAMAP3K13DLK1 | |
| SCHEMBL30748906 | 0.68 | MAP3K12 (0.42) | MAP3K12MTORPIK3CAMAP3K13 | |
| SCHEMBL18339649 | 0.68 | MAP3K12 (0.42) | MAP3K12MTORPIK3CAMAP3K13 | |
| SCHEMBL25082160 | 0.65 | MAP3K12 (0.46) | MAP3K12MTORPIK3CAMAP3K13 | |
| SCHEMBL20742465 | 0.63 | MAP3K12 (0.45) | MAP3K12MTORPIK3CAMAP3K13 | |
| SCHEMBL15743911 | 0.63 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL25147712 | 0.63 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL15743920 | 0.63 | MAP3K12 (0.50) | MAP3K12MAP3K13DLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152239-A1 | BENZAMIDE AND HETEROBENZAMIDE COMPOUNDS | HRH2, HRH4, H1-0 | MAP3K12 3611/4885MTOR 3556/4885PIK3CA 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.